Showing 1,101 - 1,120 results of 3,265 for search '"hematology"', query time: 0.07s Refine Results
  1. 1101
  2. 1102
  3. 1103
  4. 1104
  5. 1105
  6. 1106
  7. 1107

    Development and validation of predictive models of early immune effector cell–associated hematotoxicity by Emily C. Liang, Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz-Maldonado, Aya Albittar, Natalie Wuliji, Ryan Basom, Yein Jeon, Qian Wu, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Mohamed Sorror, Joshua A. Hill, Noam E. Kopmar, Rahul Banerjee, Andrew J. Cowan, Damian Green, Ajay K. Gopal, Christina Poh, Mazyar Shadman, Alexandre V. Hirayama, Brian G. Till, Erik L. Kimble, Lorenzo Iovino, Aude G. Chapuis, Folashade Otegbeye, Ryan D. Cassaday, Filippo Milano, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

    Published 2025-02-01
    “…Therefore, we performed comprehensive univariate analyses to identify factors associated with severe (grade 3-4) early ICAHT (eICAHT) in 691 patients who received commercial or investigational CAR T-cell therapy for hematologic malignancies. In univariate logistic regression, preinfusion factors associated with severe eICAHT included disease type (acute lymphoblastic leukemia), prelymphodepletion (pre-LD) blood counts including absolute neutrophil count (ANC), lactate dehydrogenase (LDH), and inflammatory (C-reactive protein [CRP], ferritin, and interleukin-6 [IL-6]) and coagulopathy biomarkers (D-dimer). …”
    Get full text
    Article
  8. 1108
  9. 1109
  10. 1110
  11. 1111
  12. 1112
  13. 1113

    Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis by Haihang Zhang, Junhao Zeng, Fangling Zhang, Jing Liu, Long Liang

    Published 2025-01-01
    “…The dysregulation of BCL11A disrupts downstream molecular pathways, contributing to the development of several hematological malignancies, particularly leukemias. This review provides a comprehensive overview of the role of BCL11A in normal and malignant hematopoiesis, details the hematological disorders associated with its dysregulation and explores the current therapeutic strategies targeting this transcription factor.…”
    Get full text
    Article
  14. 1114
  15. 1115
  16. 1116
  17. 1117
  18. 1118
  19. 1119
  20. 1120